Aastrom Moves Cell Therapy Into Phase III
This article was originally published in The Pink Sheet Daily
Executive Summary
The biotech talked about its late-stage clinical plans during a second quarter conference call.
You may also be interested in...
Aastrom Adds Revenues Through $6.5M Regen Med Buy From Sanofi
The stem cell company will use revenues from the already-marketed products to continue funding the late-stage stem cell therapy in its pipeline and help it build out its commercial organization.
Aastrom Stands Behind Its Decision To Shift Gears In Late Stages
The Michigan biotech is undergoing a complete restructuring as it cans its lead program and new management implements a different vision for the company.
France's Cellectis To Acquire Cellartis To Produce A Leader In Stem Cell Technologies
The genome engineering company, Cellectis, is to acquire the Swedish human embryonic stem cell firm Cellartis in a €30 million deal expected to complete at the end of October.